Systemic lidocaine for neuropathic pain relief

Area of Science:

• Pain Management
• Neurology
• Pharmacology

Background:

• Systemic lidocaine has been used for over 35 years to treat acute and chronic pain.
• It is a diagnostic and therapeutic tool for intractable neuropathic pain.
• Oral lidocaine congeners like mexiletine have expanded its use in chronic pain.

Purpose of the Study:

• Address clinical issues in lidocaine therapy for neuropathic pain.
• Clarify the effective dose range for lidocaine testing.
• Determine the predictive value of lidocaine tests for oral congener trials.
• Identify specific pain symptoms relieved by lidocaine.
• Compare therapeutic effects and long-term outcomes of lidocaine and its oral congeners.

Main Methods:

• Review of existing clinical data and research on systemic lidocaine and its oral congeners.
• Analysis of proposed central and peripheral mechanisms of action.
• Consideration of recent findings on sodium channel alterations in neuropathic pain.

Main Results:

• Clinical issues remain regarding optimal dosing, predictive value of tests, and comparative efficacy.
• Mechanisms of neuropathic pain relief by lidocaine are not fully understood, with both central and peripheral theories.
• Systemic lidocaine may suppress ectopic nerve discharges without blocking normal conduction.
• Changes in tetrodotoxin (TTX)-sensitive and TTX-resistant sodium channels are linked to neuropathic pain.

Conclusions:

• Further research is needed to establish effective dosing and predictive value for lidocaine therapy.
• Understanding lidocaine's mechanisms and exploring subtype-specific sodium channel blockers could improve neuropathic pain management.
• Systemic lidocaine and its congeners offer therapeutic potential, but inconsistencies in application persist.